Adult Malignant Glioma Therapeutics Market Size, Share, Growth Analysis, Business Insights And Forecast To 2033

The adult malignant glioma therapeutics market size has grown rapidly in recent years. It will grow from $2.03 billion in 2023 to $2.25 billion in 2024 at a compound annual growth rate (CAGR) of 10.5%. The growth in the historic period can be attributed to increased incidence rates, patient advocacy initiatives, personalized medicine approaches..

The adult malignant glioma therapeutics market size is expected to see strong growth in the next few years. It will grow to $3.23 billion in 2028 at a compound annual growth rate (CAGR) of 9.5%. The growth in the forecast period can be attributed to immunotherapy advancements, targeted therapies, biomarker discoveries, liquid biopsy applications, expanded access programs.. Major trends in the forecast period include patient-centric drug development, fast-track and breakthrough designation, advances in drug delivery systems, collaborative research initiative, integration of artificial intelligence..

Market Overview -
An adult malignant glioma is a type of brain tumor that originates in the glial cells of the brain or spinal cord. Adult malignant glioma therapeutics refers to the various treatment options available for malignant gliomas in adults, aiming to improve quality of life and prolong survival.

Download Free Sample of Report -
https://www.thebusinessresearchcompany.com/sample.aspx?id=13178&type=smp

Rising Incidence Of Brain Tumors Fuels Growth In The Adult Malignant Glioma Therapeutics Market
The growing cases of brain tumors are expected to drive the adult malignant glioma therapeutics market growth. A brain tumor is an abnormal mass of tissue in which the normal systems that regulate cells appear not to affect the uncontrollable growth and multiplication of the cells. Adult malignant glioma is a type of brain tumor made up of cells that grow abnormally and uncontrollably. Adult malignant glioma treatment treats brain tumors by combining surgery, radiation therapy, and chemotherapy. For instance, in January 2023, according to the American Cancer Society, a US-based nonprofit cancer advocacy organization, the number of brain and nervous system cancer cases increased to 24,810 in 2023, reflecting a growth of 3.85% from 23,890 in 2020. Therefore, the growing cases of brain tumors are driving the adult malignant glioma therapeutics market.

Competitive Landscape -
Major companies operating in the adult malignant glioma therapeutics market report are Johnson & Johnson Private Limited, Pfizer Inc., Bio-Rad Laboratories Inc., F. Hoffmann-La Roche Ltd., Allergan plc, AbbVie Inc., Novartis AG, Bayer AG, Merck & Co Inc., GlaxoSmithKline plc, Bristol-Myers Squibb Company, Abbott Laboratories, AstraZeneca plc, Eli Lilly and Company, Amgen Inc., Teva Pharmaceutical Industries Ltd., GT Medical Technologies Inc., Lupin Limited, Mylan NV, Sanofi SA, Bausch Health Companies Inc., Sun Pharmaceutical Industries Ltd., Aurobindo Pharma Limited, Genetech Inc., Amneal Pharmaceuticals LLC, Emcure Pharmaceuticals Limited, Novocure Ltd., Arbour Pharmaceuticals LLC, Basilea Pharmaceuticals Ltd.

Innovations In Small Molecule Targeted Degraders For Adult Malignant Glioma Therapeutics
Major companies operating in the adult malignant glioma therapeutics market are developing innovative products, such as small molecule targeted degraders, to provide reliable customer service. A small-molecule targeted degrader is a drug that uses small molecules to induce the degradation of specific proteins by targeting the protein of interest (POI) and an E3 ubiquitin ligase. For instance, in February 2023, Beactica Therapeutics AB, a Sweden-based precision oncology company, received orphan drug designation approval from the U.S. Food and Drug Administration (FDA) for BEA-17 to treat glioblastoma (GBM). It is a small-molecule targeted degrader of the epigenetic enzyme LSD1 and its co-factor CoREST that has been implicated in the pathogenesis of various cancers, including GBM. BEA-17 works by degrading LSD1 and CoREST, which leads to the reactivation of tumor suppressor genes and the inhibition of cancer cell growth.

Browse Full Report @
https://www.thebusinessresearchcompany.com/report/adult-malignant-glioma-therapeutics-global-market-report

Key Segments -
The adult malignant glioma therapeutics market covered in this report is segmented -
1) By Type Of Disease: Glioblastoma Multiforme, Anaplastic Astrocytoma, Anaplastic Oligodendroglioma, Anaplastic Oligoastrocytoma, Other Types
2) By Therapy: Chemotherapy, Targeted Therapy, Radiotherapy, Other Therapies
3) By End-User: Hospitals, Specialty Clinics, Cancer And Radiation Therapy Centers, Other End Users

Key highlights covered in the report -
1. Detailed market size forecast and historical data analysis
2. Key drivers influencing market growth
3. Identification of upcoming trends and potential opportunities in the market
4. Analysis of major players strategies, to understand competitive dynamics and market positioning
5. Evaluation of regional dynamics

Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Want To Know More About The Business Research Company?

The Business Research Company (www.thebusinessresearchcompany.com) is a market intelligence firm that pioneers in company, market, and consumer research. Located globally, TBRC's consultants specialise in various industries including manufacturing, healthcare, financial services, chemicals, and technology.

Global Market Model - World's Most Comprehensive Database

The Business Research Company's flagship product, Global Market Model (www.thebusinessresearchcompany.com/global-market-model) is a market intelligence platform covering various macroeconomic indicators and metrics across 60 geographies and 27 industries. The Global Market Model covers multi-layered datasets which help its users assess supply-demand gaps

This release was published on openPR.